HESLOP, Helen E. 
FF 
Principal Investigator/Program Director (Last, first, middle): 
BIOGRAPHICAL SKETCH 
Give the following information for the key personnel and consultants and collaborators. Begin with the principal 
investigator/program director. Photocopy this page for each person. 
NAME POSITION TITLE 
Assistant Member, Division of Bone Marrow 
HESLOP, Helen Elisabeth Transplantation, Dept, of Hematology-Oncology 
EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION 
DEGREE 
YEAR 
CONFERRED 
FIELD OF STUDY 
University of Otago, Dunedin, New Zealand 
MB ChB 
1980 
Medicine 
Royal Australasian College of Physicians 
FRACP 
1987 
Medicine 
Royal Australasian College of Pathologists 
i FRCPA 
1987 
Hemat/ Immunol 
University of Otago, Dunedin, New Zealand 
MD 
1990 
Hematology 
RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list, in chronological order, previous employment, experience, and 
honors. Key personnel include the principal investigator and any other individuals who participate in the scientific development or execution of the project. 
Key personnel typically will include all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or 
baccalaureate level provided they contribute in a substantive way to the scientific development or execution of the project. Include present membership on 
any Federal Government public advisory committee. List, in chronological order, the titles, all authors, and complete references to all publications during the 
past three years and to representative earlier publications pertinent to this application. DO NOT EXCEED TWO PAGES. 
1980-82 
1982-84 
1984-85 
1986-89 
1989-91 
1991 to 
present 
1991 to 
present 
House Officer/Senior House Officer, Canterbury Hospital Board, Christchurch, 
New Zealand 
Medical Registrar, Canterbury Hospital Board, Christchurch, New Zealand 
Senior Registrar in Hematology, Canterbury Hospital Board, Christchurch, New 
Zealand 
Research Fellow/Honorary Lecturer, Royal Free Hospital, London, England 
Postdoctoral Research Associate, Department of Biochemistry and Hematology- 
Oncology, St. Jude Children's Research Hospital, Memphis, TN 
Assistant Professor, Department of Pediatrics, University of 
Tennessee, Memphis, College of Medicine, Tennessee 
Assistant Member, Disivison of Bone Marrow Transplantation, 
Department of Hematology-Oncology, St. Jude Children's Research Hospital, 
Memphis, Tennessee 
PUBLICATIONS (From a total of 46) 
Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, 
Meager A, Brenner MK. Tumour necrosis factor as an autocrine tumour growth factor 
for chronic B cell malignancies. Lancet i:969-971, 1988. 
Heslop HE, Price GM, Prentice HG, Cordingley FT, Webster ADB , Hoffbrand AV, Brenner MK. 
In vitro analysis of the interactions of recombinant IL2 with regenerating lymphoid 
and myeloid cells after allogeneic marrow transplantation. J Immunol 140:3461- 
3466, 1988. 
Bianchi ACM, Heslop HE, Drexler HG, Cordingley FT, Turner M, De Mel WCP, Hoffbrand AV, 
Brenner MK. Effects of tumour necrosis factor and a interferon on chronic B cell 
malignancies. Nouv Rev Fr Heamtol 30:317-319, 1988. 
Reittie JE, Gottlieb DJ, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, 
Prentice HG, Brenner MK. Endogenously activated killer cells circulate after 
autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 
73:1351-1358, 1989. 
Heslop HE, Gottlieb DJ, Reittie JE, Bello-Fernandez C, Meager A, Prentice HG, Brenner MK. 
Spontaneous and Interleukin 2 induced secretion of tumour necrosis factor and gamma 
interferon following autologous marrow transplantation or chemotherapy. Br J 
Haematol 72:122-126, 1989. 
Gottlieb DJ, Brenner MK, Heslop HE, Bianchi ACM, Bello-Fernandez C, Mehta AB, Newland AC, 
Galazka AR, Scott ES, Hoffbrand AV, Prentice HG. A phase 1 clinical trial of 
recombinant Interleukin 2 following high dose chemoradiotherapy for haematological 
malignancy: Applicability to the elimination of minimal residual disease. Br J 
FQ 
PHS 398 (Rev' 
Number p, 
?er 6U : 610-blb , lyuy. 
ecutively at the bottom throughout the application 
Do°Z u P se 9 s e uft 6 !e P s a s 9 ufemh i nant DNA Research, Volume 17 
FF 
